Bepotastine Besilate (Page 2 of 2)
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Bepotastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from mast cells.
12.3 Pharmacokinetics
Absorption: The extent of systemic exposure to bepotastine following topical ophthalmic administration of bepotastine besilate 1% and 1.5% ophthalmic solutions was evaluated in 12 healthy adults. Following one drop of 1% or 1.5% bepotastine besilate ophthalmic solution to both eyes four times daily (QID) for 7 days, bepotastine plasma concentrations peaked at approximately 1 to 2 hours post-instillation. Maximum plasma concentrations for the 1% and 1.5% strengths were 5.1 ± 2.5 ng/mL and 7.3 ± 1.9 ng/mL, respectively. Plasma concentrations at 24 hours post-instillation were below the quantifiable limit (2 ng/mL) in 11/12 subjects in the two dose groups.
Distribution: The extent of protein binding of bepotastine is approximately 55% and independent of bepotastine concentration.
Metabolism: In vitro metabolism studies with human liver microsomes demonstrated that bepotastine is minimally metabolized by CYP450 isozymes. In vitro studies demonstrated that bepotastine besilate does not inhibit the metabolism of various cytochrome P450 substrates via inhibition of CYP3A4, CYP2C9, and CYP2C19. The effect of bepotastine besilate on the metabolism of substrates of CYP1A2, CYP2C8, and CYP2D6 was not studied. Bepotastine besilate has a low potential for drug interaction via inhibition of CYP3A4, CYP2C9, and CYP2C19.
Excretion: The main route of elimination of bepotastine besilate is urinary excretion (with approximately 75-90% excreted unchanged in urine).
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
Long-term dietary studies in mice and rats were conducted to evaluate the carcinogenic potential of bepotastine besilate. Bepotastine besilate did not significantly induce neoplasms in mice receiving a nominal dose of up to 200 mg/kg/day for 21 months, or in rats receiving a nominal dose of up to 97 mg/kg/day for 24 months. These dose levels correspond to systemic exposures approximately 350 and 200 times higher than that achieved at the RHOD, respectively.
The no observable adverse effect level for bepotastine besilate based on nominal dose levels in carcinogenicity tests were 18.7 to 19.9 mg/kg/day in mice and 9.6 to 9.8 mg/kg/day in rats (corresponding to systemic exposures approximately 60 and 20 times higher than that anticipated in humans at RHOD, respectively).
Mutagenesis
There was no evidence of genotoxicity in the Ames test (mutagenicity), in CHO cells (chromosome aberration), in mouse hepatocytes (unscheduled DNA synthesis), or in the mouse micronucleus test.
Impairment of Fertility
Oral administration of bepotastine to male and female rats at doses up to 1,000 mg/kg/day (5,400 times higher than the maximum RHOD, on a mg/m2 basis) resulted in reduction in fertility index and surviving fetuses. Oral administration of bepotastine besilate produced no observed adverse effects on fertility or reproduction in rats at oral doses up to 200 mg/kg/day (corresponding to an estimated blood plasma concentration 3,300 times higher than that anticipated in humans at the RHOD).
14 CLINICAL STUDIES
Clinical efficacy was evaluated in two conjunctival allergen challenge (CAC) studies (237 patients). Bepotastine Besilate Ophthalmic Solution, 1.5% was more effective than its vehicle for relieving ocular itching induced by an ocular allergen challenge, both at a CAC 15 minutes post-dosing and a CAC 8 hours post-dosing of Bepotastine Besilate Ophthalmic Solution.
The safety of Bepotastine Besilate Ophthalmic Solution was evaluated in a randomized clinical study of 861 subjects over a period of 6 weeks.
16 HOW SUPPLIED/STORAGE AND HANDLING
Bepotastine Besilate Ophthalmic Solution, 1.5% is supplied in a white low density polyethylene bottle with a sterile linear low density polyethylene controlled dropper tip and a white polypropylene cap in the following sizes:
NDC 82260-630-05 5 mL Bottle
NDC 82260-630-10 10 mL Bottle
Storage:
Store at 15°C to 25°C (59°F to 77°F).
17 PATIENT COUNSELING INFORMATION
- •
- Sterility of Dropper Tip
- Advise patients not to touch the dropper tip to any surface, as this may contaminate the solution and to keep the bottle tightly closed when not in use.
Distributed by:
Bausch & Lomb Americas Inc.
Bridgewater, NJ 08807 USA
Manufactured by:
Bausch & Lomb Incorporated
Tampa, FL 33637 USA
Under license from:
Senju Pharmaceutical Co., Ltd.
Osaka, Japan 541-0046
U.S. Patent Numbers: 8,784,789 and 8,877,168
© 2022 Bausch & Lomb Incorporated or its affiliates
9751301 (folded)
9751401 (flat)
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
NDC 82260-630-05
Bepotastine
Besilate
Ophthalmic
Solution
1.5%
Sterile
FOR TOPICAL
OPHTHALMIC USE
Rx only
5 mL
BAUSCH + LOMB
9751001 MA52107
BEPOTASTINE BESILATE bepotastine besilate solution/ drops | |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
|
Labeler — Bausch & Lomb Americas Inc. (118287629) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Bausch & Lomb Incorporated | 079587625 | MANUFACTURE (82260-630), LABEL (82260-630), PACK (82260-630) |
Revised: 08/2022 Bausch & Lomb Americas Inc.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/bepotastine-besilate-2/page/2/